Poseida Therapeutics Inc

Poseida Therapeutics — Investor Day (February 2023)

145 slides from Poseida Therapeutics's investor day presentation, Feb 22, 2023

  1. Slide 1: A New Class of Cell & Gene Therapies With the Capacity to Cure

    Slide 1: A New Class of Cell & Gene Therapies With the Capacity to Cure

    A New Class of Cell & Gene Therapies With the Capacity to Cure February 22, 2023 Exhibit 99.2

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    Disclaimer | POSEIDA R&D DAY 2023 This presentation and any accompanying oral commentary contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts and include, w

  3. Slide 3: Welcome & Introduction

    Slide 3: Welcome & Introduction

    Welcome & Introduction Eric M. Ostertag, MD, PhD Founder

  4. Slide 4: Agenda

    Slide 4: Agenda

    Agenda Introduction Eric M. Ostertag, MD, PhD, Founder Fireside Chat George Church, PhD, Gene Editing Pioneer & Chair, Poseida Gene Therapy SAB Gene Therapy Brent Warner, President, Gene Therapy Fireside Chat Madhu Natarajan, PhD, Head, Rare Diseases Drug Discovery Unit, Takeda Pipeline Programs Jac

  5. Slide 5: Fireside Chats: Guest Speakers

    Slide 5: Fireside Chats: Guest Speakers

    Fireside Chats: Guest Speakers Christine Brown, PhD Professor, City of Hope; CAR-T Expert; and Member, Poseida Immuno-Oncology SAB George Church, PhD Gene Editing Pioneer and Chair, Poseida Gene Therapy SAB Madhu Natarajan, PhD Head, Rare Diseases Drug Discovery Unit – Takeda | POSEIDA R&D DAY 2023

  6. Slide 6: Gene Therapy (GTx)

    Slide 6: Gene Therapy (GTx)

    Gene Therapy (GTx) Brent Warner February 22, 2023 President, Gene Therapy

  7. Slide 7: Robust Platform Technologies Supporting Our GTx Pipeline Programs

    Slide 7: Robust Platform Technologies Supporting Our GTx Pipeline Programs

    Robust Platform Technologies Supporting Our GTx Pipeline Programs Current Platforms Super piggyBac® (SPB) Non-viral transposon gene insertion technology SPB Hybrid AAV + LNP Gene insertion technology utilizing AAV as DNA donor Site-Specific Super piggyBac® (ssSPB) Next generation programmable gene t

  8. Slide 8: Focus on Accelerating Programs and Platforms

    Slide 8: Focus on Accelerating Programs and Platforms

    Focus on Accelerating Programs and Platforms Accelerate Programs Advance current programs towards IND / clinical readiness Disseminate data at upcoming congresses Enhance Platforms Accelerate ssSPB to become a leading Gene Editing Platform Breadth and depth across proprietary LNP portfolio Strengthe

  9. Slide 9: GTx Pipeline Programs

    Slide 9: GTx Pipeline Programs

    GTx Pipeline Programs Jack Rychak Vice President, Research and Development – GTx

  10. Slide 10: Powerful Platforms Enabling Innovative Gene Therapy Products

    Slide 10: Powerful Platforms Enabling Innovative Gene Therapy Products

    Powerful Platforms Enabling Innovative Gene Therapy Products SPB Gene Insertion Hybrid Delivery System + Transposon Transposase | POSEIDA R&D DAY 2023 Highly efficient integration of therapeutic transgene into genome Leverage mature AAV and LNP delivery technology for challenging diseases + Non-Vira

  11. Slide 11: SPB Non-Viral and Hybrid Advantages Over Standard AAV

    Slide 11: SPB Non-Viral and Hybrid Advantages Over Standard AAV

    SPB Non-Viral and Hybrid Advantages Over Standard AAV 1) Kang et al., Mol. Ther. Methods Clin. 2019; 2) Zhong et al., Hum. Gene Ther. 2013; 3) Donsante et al., Science 2007; 4) Chandler et al., J. Clin. Invest. 2015; 5) Walia et al., Mol. Ther. 2015; 6) Li et al., Mol. Ther. 2021 Non-Viral Delivery

  12. Slide 12: Robust Platform Technologies Supporting Our GTx Pipeline Programs

    Slide 12: Robust Platform Technologies Supporting Our GTx Pipeline Programs

    Current Platforms Super piggyBac® (SPB) Non-viral transposon gene insertion technology SPB Hybrid AAV + LNP Gene insertion technology utilizing AAV as DNA donor Site-Specific Super piggyBac® (ssSPB) Next generation programmable gene targeting/editing system Cas-CLOVER™ High fidelity gene editing sys

  13. Slide 13: P-OTC-101 Poseida Internal Program

    Slide 13: P-OTC-101 Poseida Internal Program

    P-OTC-101 Poseida Internal Program Bernard Kok Associate Director, Pharmacology – GTx

  14. Slide 14: Ornithine Transcarbamylase Deficiency (OTCD) – High Unmet Need

    Slide 14: Ornithine Transcarbamylase Deficiency (OTCD) – High Unmet Need

    Ornithine Transcarbamylase Deficiency (OTCD) – High Unmet Need X-linked metabolic liver disorder causing toxic ammonia build-up Most common urea cycle disorder and most common cause of 'early onset' illness1 NH3 build-up -> neurological impairment / death Dietary protein restriction & alternative pa

  15. Slide 15: AAV Alone is Not Effective or Durable to Rescue Severe OTCD

    Slide 15: AAV Alone is Not Effective or Durable to Rescue Severe OTCD

    AAV Alone is Not Effective or Durable to Rescue Severe OTCD | POSEIDA R&D DAY 2023 0 Days after birth 46 mOTC shRNA Hyperammonemia hOTC AAV 1 hOTC AAV alone failed to rescue severe OTCD at all doses due to lack of durability from non-integrating AAV Untreated hOTC AAV Experimental Design: Neonatal O

  16. Slide 16: Goal is to Deliver Functional Cures with Hybrid P-OTC-101

    Slide 16: Goal is to Deliver Functional Cures with Hybrid P-OTC-101

    Goal is to Deliver Functional Cures with Hybrid P-OTC-101 Biodegradable nanoparticle transiently delivers SPB Efficient integration in growing liver enables: Durable OTC expression Potentially a functional cure Potential for neonatal/juvenile patients Therapeutic protein levels with 1/10th the AAV d

  17. Slide 17: P-OTC-101 Achieved Expression of OTC Leading to Functional Cure

    Slide 17: P-OTC-101 Achieved Expression of OTC Leading to Functional Cure

    P-OTC-101 Achieved Expression of OTC Leading to Functional Cure >50% OTC SPB LNP + hOTC AAV <3% OTC hOTC AAV + Percent hepatocytes with OTC expression: | POSEIDA R&D DAY 2023 100% Rescue of Mortality in OTCD Model 0.2 mg/kg SPB transposase LNP + 2E13 vg/kg hOTC AAV or AAV alone administered on day 1

  18. Slide 18: SPB LNP Enables Plug 'n Play with Different AAV Capsids

    Slide 18: SPB LNP Enables Plug 'n Play with Different AAV Capsids

    SPB LNP Enables “Plug ‘n Play” with Different AAV Capsids | POSEIDA R&D DAY 2023 untreated AAV9 only AAV3d only SPB LNP + AAV8 SPB LNP + AAV9 SPB LNP + AAV3d OTC activity (dark brown) + SPB LNP AAV8 AAV9 AAV3-derivative OR OR SPB mRNA LNPs were co-administered with AAV serotypes encapsulating hOTC t

  19. Slide 19: Strong Efficacy Seen Across Wide AAV Dose Range for P-OTC-101

    Slide 19: Strong Efficacy Seen Across Wide AAV Dose Range for P-OTC-101

    Strong Efficacy Seen Across Wide AAV Dose Range for P-OTC-101 | POSEIDA R&D DAY 2023 Molecular Readouts Disease Biomarkers Over a wide AAV dose range, Poseida’s AAV-LNP system provides high transgene levels and efficacy (decreased disease biomarkers) 0.5 mg/kg SPB mRNA LNP + dose titration of hOTC A

  20. Slide 20: SPB mRNA LNP Dose Response Enabled Titrated Correction

    Slide 20: SPB mRNA LNP Dose Response Enabled Titrated Correction

    SPB mRNA LNP Dose Response Enabled Titrated Correction | POSEIDA R&D DAY 2023 SPB LNP levels are the primary driver of dose titratability for transgene levels and disease correction Molecular Readouts Disease Biomarkers Dose titration of SPB mRNA LNP + 2E13 vg/kg hOTC AAV administered to neonatal OT

  21. Slide 21: P-OTC-101 Demonstrated Favorable Tolerability

    Slide 21: P-OTC-101 Demonstrated Favorable Tolerability

    P-OTC-101 Demonstrated Favorable Tolerability | POSEIDA R&D DAY 2023 Clinical Chemistry – Liver Tox Markers Minimal impact on clinical chemistry at high SPB mRNA LNP and hOTC AAV doses 40 days post-treatment in OTCD mice compared to hOTC AAV alone or untreated Untreated 2E13 AAV only 0.5 mg/kg + 2E1

  22. Slide 22: P-OTC-101 Provided a Durable Response in OTCD Mouse Models

    Slide 22: P-OTC-101 Provided a Durable Response in OTCD Mouse Models

    P-OTC-101 Provided a Durable Response in OTCD Mouse Models Severe disease challenge 0 Days after birth AAV 1 ± LNP 243 mOTC shRNA AAV only LNP + AAV | POSEIDA R&D DAY 2023 hOTC AAV +/- 0.5 mg/kg SPB mRNA LNP administered to neonatal OTCD mice and analysis performed 243 to 278 days post-treatment Dur

  23. Slide 23: P-OTC-101 SPB LNP Well Tolerated in Non-Human Primate Study

    Slide 23: P-OTC-101 SPB LNP Well Tolerated in Non-Human Primate Study

    P-OTC-101 SPB LNP Well Tolerated in Non-Human Primate Study v v Liver Enzymes Biodistribution Mouse NHP Mouse NHP | POSEIDA R&D DAY 2023 Comparable SPB mRNA biodistribution in rodent and NHP No meaningful liver enzyme elevations above vehicle observed in rodent nor NHP

  24. Slide 24: P-OTC-101: Summary and Key Takeaways

    Slide 24: P-OTC-101: Summary and Key Takeaways

    P-OTC-101 (hybrid SPB LNP + AAV) rescues OTCD with a durable response Proof-of-concept for a functional cure of OTCD Provides pathway for early onset / severe OTCD, unlike standard AAVs Highlights use as a “plug-and-play” system with different AAV capsids Improvements in disease biomarkers across wi

  25. Slide 25: P-PAH-101 Partnered with Takeda

    Slide 25: P-PAH-101 Partnered with Takeda

    P-PAH-101 Partnered with Takeda Jack Rychak Vice President, Research and Development – GTx

  26. Slide 26: Phenylketonuria – Rare Disorder Without an Approved Gene Therapy

    Slide 26: Phenylketonuria – Rare Disorder Without an Approved Gene Therapy

    Phenylketonuria – Rare Disorder Without an Approved Gene Therapy Mechanism | POSEIDA R&D DAY 2023 L-Phe L-Tyr Serotonin Dopamine PAH Melanin Phe-Free Medical Diet Enzyme Agonist / Replacement 1. https://medlineplus.gov/genetics/condition/phenylketonuria/ 2. https://www.pku.com/about-pku/phe-in-the-b

  27. Slide 27: P-PAH-101 Aims to Transform Standard of Care for PKU

    Slide 27: P-PAH-101 Aims to Transform Standard of Care for PKU

    P-PAH-101 Aims to Transform Standard of Care for PKU AAV delivers therapeutic transgene, Phenylalanine hydroxylase expression cassette Biodegradable nanoparticle delivers SPB as mRNA SPB mRNA rapidly translated into protein and integration of PAH transgene into genome Significant increase in PAH tra

  28. Slide 28: P-PAH-101 Delivers Superior Hepatocyte Transduction Over AAV

    Slide 28: P-PAH-101 Delivers Superior Hepatocyte Transduction Over AAV

    AAV + Super piggyBac P-PAH-101 Delivers Superior Hepatocyte Transduction Over AAV Standard AAV | POSEIDA R&D DAY 2023 Immunofluorescence: therapeutic PAH protein stained in red; cell nuclei (DAPI) stained in blue Adult wild type mice administered 3E12 vg/kg AAV +/- 0.5 mg/kg SPB-LNP Livers collected

  29. Slide 29: P-PAH-101 Resolved Disease in Adult Mouse Model of PKU

    Slide 29: P-PAH-101 Resolved Disease in Adult Mouse Model of PKU

    P-PAH-101 Resolved Disease in Adult Mouse Model of PKU | POSEIDA R&D DAY 2023 STUDY OVERVIEW Adult male Enu2 treated on day=0 of study by single IV dose AAV comprising PAH transposon co-administered with mRNA-LNP with functional SPB or inactive SPB (control) Low AAV dose (1E12 vg/kg) Normalization o

  30. Slide 30: SPB-Mediated Integration Enables Efficacy at Lower AAV Doses

    Slide 30: SPB-Mediated Integration Enables Efficacy at Lower AAV Doses

    SPB-Mediated Integration Enables Efficacy at Lower AAV Doses | POSEIDA R&D DAY 2023 Integration potentiates PAH transgene copies delivered by AAV in adult mouse model SPB hybrid system offers potential to significantly reduce AAV dose versus standard AAV therapies hPAH Protein hPAH Vector Copies inc

  31. Slide 31: P-PAH-101 Demonstrates Potential to Treat Juvenile PKU Patients

    Slide 31: P-PAH-101 Demonstrates Potential to Treat Juvenile PKU Patients

    | POSEIDA R&D DAY 2023 STUDY OVERVIEW Juvenile mice treated on day=21 of life by IV single dose AAV comprising PAH transposon co-administered with mRNA-LNP with functional SPB or inactive SPB (control) Low AAV dose (1E12 vg/kg) with analysis 4 weeks post-treatment P-PAH-101 Demonstrates Potential to

  32. Slide 32: P-PAH-101: Summary and Key Takeaways

    Slide 32: P-PAH-101: Summary and Key Takeaways

    P-PAH-101: Summary and Key Takeaways | POSEIDA R&D DAY 2023 P-PAH-101 (SPB LNP + AAV) demonstrates ability to rescue disease Provides early proof of concept to deliver a functional cure for PKU Demonstrates ability to reduce serum PHE to normal levels following a single IV dose Highlights early abil

  33. Slide 33: P-FVIII-101 Partnered with Takeda

    Slide 33: P-FVIII-101 Partnered with Takeda

    P-FVIII-101 Partnered with Takeda Jack Rychak, PhD Vice President, Research and Development – GTx

  34. Slide 34: Hemophilia A is a Rare Disease Amenable to Gene Therapy

    Slide 34: Hemophilia A is a Rare Disease Amenable to Gene Therapy

    X-linked bleeding disorder caused by deficiency in coagulation factor VIII Large cDNA (~7.1 kb) and complex protein Severity of hemorrhagic episodes tends to correlate directly with the plasma FVIII concentration, majority of patients have severe disease (<1% FVIII activity) Gene Therapy has the pot

  35. Slide 35: Non-viral SPB May Be a Highly Efficient System for Transposing Transgenes

    Slide 35: Non-viral SPB May Be a Highly Efficient System for Transposing Transgenes

    Non-viral SPB May Be a Highly Efficient System for Transposing Transgenes Co-delivery of Both Transposon and Transposase Required for Genomic Insertion 3rd Generation SPB Transposase Transposon ITR ITR Cargo GOI Promoter pA | POSEIDA R&D DAY 2023 Formulated as double-stranded DNA Cargo comprises pro

  36. Slide 36: Lipid Nanoparticles Enable In Vivo Use of SPB for Gene Therapy

    Slide 36: Lipid Nanoparticles Enable In Vivo Use of SPB for Gene Therapy

    Lipid Nanoparticles Enable In Vivo Use of SPB for Gene Therapy hFVIII Transposon LNP Super piggyBac Transposase LNP + Therapeutic Transgene (DNA) mRNA SPB mRNA Transposase LNP FVIII DNA Transposon LNP | POSEIDA R&D DAY 2023 Biodegradable lipid nanoparticles (LNPs) deliver SPB transposase and human F

  37. Slide 37: LNP Platform is Unconstrained by Cargo Capacity Limitations

    Slide 37: LNP Platform is Unconstrained by Cargo Capacity Limitations

    Panel of hFVIII transposons with variable promoter, UTR, coding sequence, and other regulatory elements (>7Kb) Transposons formulated as LNP Transposon LNP co-administered with SPB LNP as single dose IV to juvenile mice (n=5-7) hFVIII plasma levels measured by ELISA after 1 week LNP Platform is Unco

  38. Slide 38: Durable FVIII Expression in Adult HemA Mouse With Single LNP Dose

    Slide 38: Durable FVIII Expression in Adult HemA Mouse With Single LNP Dose

    Liver Enzymes (17 Week) Durable FVIII Expression in Adult HemA Mouse With Single LNP Dose | POSEIDA R&D DAY 2023 Stable hFVIII Expression Over 16 Weeks ~20X Day 7 LNP administered as single dose IV to adult mice deficient in FVIII and tolerized to human FVIII Significant Increase in hFVIII Expressio

  39. Slide 39: Favorable Durability Following Single Dose in Neonatal Mice

    Slide 39: Favorable Durability Following Single Dose in Neonatal Mice

    Favorable Durability Following Single Dose in Neonatal Mice | POSEIDA R&D DAY 2023 FVIII Expression in Neonatal WT Mice Dual-LNP co-administered as single dose IV to neonatal (day 1 of life) BALB/c mice (n=6-9) Transposon DNA-LNP: 0.25 mg/kg Transposase mRNA-LNP: 1.0 mg/kg Human FVIII expression (pr

  40. Slide 40: Non-Viral Nanoparticle Delivery System Facilitates Repeat Dosing

    Slide 40: Non-Viral Nanoparticle Delivery System Facilitates Repeat Dosing

    FVIII Expression in Adult WT Mice Non-Viral Nanoparticle Delivery System Facilitates Repeat Dosing | POSEIDA R&D DAY 2023 Dual-LNP co-administered as single dose IV to adult (10wk) BALB/c mice on day 0, 3, 8, and 10 Transposon DNA-LNP: 0.25 mg/kg Transposase mRNA-LNP: 0.5 mg/kg hFVIII plasma levels

  41. Slide 41: P-FVIII-101: Summary and Key Takeaways

    Slide 41: P-FVIII-101: Summary and Key Takeaways

    A non-viral, liver-specific gene therapy utilizing SPB achieved and sustained normalized (>50%) hFVIII activity following a single dose Demonstrated repeat dosing, indicating potential for dose titration in mice Delivered therapeutic FVIII activity in mice following single and repeat doses Durabilit

  42. Slide 42: GTx Emerging Technology

    Slide 42: GTx Emerging Technology

    GTx Emerging Technology Blair Madison Chief Scientific Officer – GTx

  43. Slide 43: Current Platforms and Programs

    Slide 43: Current Platforms and Programs

    Current Platforms Super piggyBac® (SPB) Non-viral transposon gene insertion technology SPB Hybrid AAV + LNP Gene insertion technology utilizing AAV as DNA donor Site-Specific Super piggyBac® (ssSPB) Next generation programmable gene targeting/editing system Cas-CLOVER™ High fidelity gene editing sys

  44. Slide 44: Emerging Platform Technologies

    Slide 44: Emerging Platform Technologies

    Emerging Platform Technologies | POSEIDA R&D DAY 2023 GENE EDITING Highly precise site-specific nucleases1 Ability to edit human and mouse hepatocytes with high efficacy Major advantages: Tolerability Ease of design Low cost Multiplexing ability Cas-CLOVER™ GENE INSERTION In-house proprietary site-s

  45. Slide 45: Site-Specific Super piggyBac

    Slide 45: Site-Specific Super piggyBac

    Site-Specific Super piggyBac Blair Madison Chief Scientific Officer – GTx

  46. Slide 46: What Advantages Would Site-specific piggyBac Provide Over CRISPR Knock-ins?

    Slide 46: What Advantages Would Site-specific piggyBac Provide Over CRISPR Knock-ins?

    What Advantages Would Site-specific piggyBac Provide Over CRISPR Knock-ins? Programmable Editing Platform With Site Specificity | POSEIDA R&D DAY 2023 Genomic DNA Paste Active in non-dividing cells Large cargo capacity Simple 2-component system Re-dosable, reversible1, scarless1 LARGE Double-strand

  47. Slide 47: Developing Site-specific Transposition With ssSPB

    Slide 47: Developing Site-specific Transposition With ssSPB

    Developing Site-specific Transposition With ssSPB | POSEIDA R&D DAY 2023 Super piggyBac (SPB) Desirable profile but not site-specific External Attempts to Make Site-specific SPB1-7 3-5-fold Greater site-specificity >500-fold Greater site-specificity Site-specific SPB Desirable Less Desirable GENOME

  48. Slide 48: PBx Rescue Swaps Non-Specific With Specific DNA-Binding

    Slide 48: PBx Rescue Swaps Non-Specific With Specific DNA-Binding

    PBx Rescue Swaps Non-Specific With Specific DNA-Binding | POSEIDA R&D DAY 2023 Remove Non-specific Binding Fuse sequence-specific DBD to PBx PBx enables low/no off-target background DBD TTAA DBD Target DNA CARGO DNA PBx-DBD Fusion Rescuing PBx Integration-Defective Transposase Our Strategy Exploit s

  49. Slide 49: Our Strategy Yields Rescue of Excision-Only PBx

    Slide 49: Our Strategy Yields Rescue of Excision-Only PBx

    Our Strategy Yields Rescue of Excision-Only PBx | POSEIDA R&D DAY 2023 Results: First demonstrated rescue of integration-defective PBx mutant Unprecedented level of site-specificity: >500-fold Data here are from un-optimized SPB fusion protein Our Strategy Exploit new structure data Computational mo

  50. Slide 50: First Generation ssSPB Yields Site-specific Transposition into Genome

    Slide 50: First Generation ssSPB Yields Site-specific Transposition into Genome

    First Generation ssSPB Yields Site-specific Transposition into Genome | POSEIDA R&D DAY 2023 off-target TTAA site mutated on-target TTAA site on-target TTAA site Genomic Target Synthetic reporter delivered via lentivirus in HEK293T Site-specific delivery reconstitutes split GFP reporter Over 20% of

  51. Slide 51: Fine Tuning Identifies Ideal Spacing Between DBD Target and TTAA

    Slide 51: Fine Tuning Identifies Ideal Spacing Between DBD Target and TTAA

    Fine Tuning Identifies Ideal Spacing Between DBD Target and TTAA | POSEIDA R&D DAY 2023 TTAA-Target Spacing Ideal Too Short Too Long TTAA DBD Target TTAA DBD Target DBD Family A DBD DBD CARGO DNA TTAA DBD Target

  52. Slide 52: Non-palindromic Targets Validated With Heterodimeric ssSPB

    Slide 52: Non-palindromic Targets Validated With Heterodimeric ssSPB

    Non-palindromic Targets Validated With Heterodimeric ssSPB: Yields ~40% GFP+ ssSPB Functions as Heterodimer for Bipartite Targets | POSEIDA R&D DAY 2023 TTAA TTAA Target A Target B DBD DBD SSv7 heterodimer Target A Target B High efficiency maintained as heterodimer GFP episomal reporter in HEK293T

  53. Slide 53: Alternative Fusion Designs Expand Targeting Range of Family A ssSPB

    Slide 53: Alternative Fusion Designs Expand Targeting Range of Family A ssSPB

    DBD Family A Alternative Fusion Designs Expand Targeting Range of Family A ssSPB Varying Spacing and Fusion Location Reveals 3 Ideal Combinations | POSEIDA R&D DAY 2023 Design Trend Identified Correlation between PBx fusion site and TTAA-DBD target spacer length Episomal Site-Specific Transposition

  54. Slide 54: Expanding The Programmability of ssSPB With Additional DBD Family

    Slide 54: Expanding The Programmability of ssSPB With Additional DBD Family

    Expanding The Programmability of ssSPB With Additional DBD Family | POSEIDA R&D DAY 2023 Wide Range of Targetable Sequences Rational design used to generate ssSPB with distinct families of programable DBDs Distinct DBD families prefer sequences with different characteristics (e.g., GC content) Great

  55. Slide 55: Plug and Play Programmability With ssSPB

    Slide 55: Plug and Play Programmability With ssSPB

    Plug and Play Programmability With ssSPB | POSEIDA R&D DAY 2023 TTAA-Target Spacing Structure Predicted Ideal Spacing %GFP+ Cells (Site-Specific Transposition) Not Tested Not Tested Not Tested Not Tested TTAA-Target Spacing Ideal Too Short Too Long CARGO DNA TTAA TTAA DBD Target TTAA DBD Target DBD

  56. Slide 56: Fine-Tuning the PBx Fusion Position with DBD-B

    Slide 56: Fine-Tuning the PBx Fusion Position with DBD-B

    Fine-Tuning the PBx Fusion Position with DBD-B Varying Spacing Reveals Enhanced Activity of ssSPB | POSEIDA R&D DAY 2023 Episomal Site-Specific Transposition Room For Improvement on Fusion Design Twenty additional fusion sites on PBx tested with our current target spacer length Several new fusions o

  57. Slide 57: Robust Genome Editing Achieved at Tooling Site

    Slide 57: Robust Genome Editing Achieved at Tooling Site

    Robust Genome Editing Achieved at Tooling Site | POSEIDA R&D DAY 2023 Genomic Site-Specific Transposition at Site-X Episomal Site-Specific Transposition TTAA xTTAAx Robust site-specific transposition characterized: High editing at target sites 1, 2, and 3 ID’d xTTAAx as new feature for optimal targe

  58. Slide 58: Titrating Activity For Optimal Integration, Without Compromising Fidelity

    Slide 58: Titrating Activity For Optimal Integration, Without Compromising Fidelity

    Titrating Activity For Optimal Integration, Without Compromising Fidelity Approach: Alter Interactions With DNA to Enhance Transposition | POSEIDA R&D DAY 2023 Strategy: Site-saturation mutagenesis Multiple positions targeted within SPB 6 mutants increase site-specific integration (episomal) Tested

  59. Slide 59: Mutations That Enhance Integration Preserve Fidelity

    Slide 59: Mutations That Enhance Integration Preserve Fidelity

    Mutations That Enhance Integration Preserve Fidelity Success: Altering Interactions With DNA Enhances Transposition | POSEIDA R&D DAY 2023 Mutations assessed for effects on random (off-target) integration Evaluate genomic on-target integration Two mutations increase integration without raising off-t

  60. Slide 60: ssSPB: Summary and Key Takeaways

    Slide 60: ssSPB: Summary and Key Takeaways

    Site-specific transposition attained an impressive rate with up to 60% of haploid genomes Specific context at TTAA reveal key features for enhanced transposition Optimization reveals new favorable fusion locations within PBx Enhancing integration is attainable without increasing off-target integrati

  61. Slide 61: Liver-Directed Gene Editing and Insertion with Cas-CLOVER

    Slide 61: Liver-Directed Gene Editing and Insertion with Cas-CLOVER

    Liver-Directed Gene Editing and Insertion with Cas-CLOVER™ Oscar Alvarez Associate Director, Genetic Engineering

  62. Slide 62: Cas-CLOVER: Clean Gene Editing

    Slide 62: Cas-CLOVER: Clean Gene Editing

    Cas-CLOVER: Clean Gene Editing 3’ 5’ 5’ 3’ Cas-CLOVER Gene Editing System Potentially the Cleanest Gene Editing Platform Extensively vetted for off-target effects in peer-reviewed publication1 Key ability to efficiently edit single or multiple genes Fully non-viral approach for in vivo gene editing

  63. Slide 63: Advantages of Fully Non-viral Cas-CLOVER for In Vivo Gene Therapies

    Slide 63: Advantages of Fully Non-viral Cas-CLOVER for In Vivo Gene Therapies

    Advantages of Fully Non-viral Cas-CLOVER for In Vivo Gene Therapies Combining Poseida Platforms to Enable Potentially Curative Therapies | POSEIDA R&D DAY 2023 3’ 5’ 5’ 3’ Cas-CLOVER Gene Editing System Non-Viral Delivery System Donor DNA mRNA/gRNA High fidelity High editing efficiency Multiplexing

  64. Slide 64: PCSK9 Knock-out Used to Demonstrate Cas-CLOVER Editing in Liver

    Slide 64: PCSK9 Knock-out Used to Demonstrate Cas-CLOVER Editing in Liver

    Mouse Pcsk9 Gene PCSK9 Knock-out Use to Demonstrate Cas-CLOVER Editing in Liver Hepatocytes 3’ 5’ 5’ 3’ Cas-CLOVER Gene Editing System Cas-CLOVER mRNA Pcsk9-targeting gRNAs Indel Loss of Function LNP Assay: Liver editing (NGS) Serum PCSK9 (ELISA) | POSEIDA R&D DAY 2023

  65. Slide 65: Efficient Cas-CLOVER Delivery and Editing in Mouse Liver

    Slide 65: Efficient Cas-CLOVER Delivery and Editing in Mouse Liver

    DNA Editing (NGS) Efficient Cas-CLOVER Delivery and Editing in Mouse Liver | POSEIDA R&D DAY 2023 Cas-CLOVER in vivo liver editing with high efficiency Cas-CLOVER mRNA and gRNAs were delivered using Poseida proprietary LNP Clear dose response effect Poseida LNP efficacy is maximal at 2 mg/kg (65% in

  66. Slide 66: More Potent LNP Enable Lower Doses While Maintaining Efficacy

    Slide 66: More Potent LNP Enable Lower Doses While Maintaining Efficacy

    More potent LNP Enable Lower Doses While Maintaining Efficacy 2nd Generation Cas-CLOVER LNPs Boost Editing by 4-fold | POSEIDA R&D DAY 2023 Cas-CLOVER LNP process optimization: 1st generation LNP 2nd generation LNP Cas-CLOVER protein engineering mRNA chemical and sequence optimization gRNA chemical

  67. Slide 67: Cas-CLOVER Lipid Nanoparticles Have Favorable Toxicity Profile

    Slide 67: Cas-CLOVER Lipid Nanoparticles Have Favorable Toxicity Profile

    Cas-CLOVER Lipid Nanoparticles Have Favorable Toxicity Profile | POSEIDA R&D DAY 2023 Cas-CLOVER LNPs very low hepatotoxicity / immunogenicity Liver enzyme levels (AST/ALT) in serum after dosing are maintained within normal range Minimal elevation of IL6 and IFNγ serum levels after dosing that resol

  68. Slide 68: Cas-CLOVER LNPs Enable Editing of Human Hepatocytes In Vivo

    Slide 68: Cas-CLOVER LNPs Enable Editing of Human Hepatocytes In Vivo

    Cas-CLOVER LNPs Enable Editing of Human Hepatocytes In Vivo | POSEIDA R&D DAY 2023 Cas-CLOVER edits human hepatocytes in mouse model Mice with humanized-liver (TK-Nog) were treated with a single injection Cas-CLOVER LNP targeting human B2M Treated mice show successful editing of B2M exon 1 – 45-50%

  69. Slide 69: Strategy for Cas-CLOVER Site-Specific Transgene Integration in Liver

    Slide 69: Strategy for Cas-CLOVER Site-Specific Transgene Integration in Liver

    Strategy for Cas-CLOVER Site-Specific Transgene Integration in Liver | POSEIDA R&D DAY 2023 Hepatocytes Single LNP Cas-CLOVER mRNA Alb-targeting gRNAs Donor DNA with transgene Cas-CLOVER for Donor DNA Integration at Alb Mouse Alb Gene Albumin intron AKAluc Bi-directional Donor DNA Cas-CLOVER Cut Sit

  70. Slide 70: Non-viral Cas-CLOVER Achieves Site-Specific Integration / Expression

    Slide 70: Non-viral Cas-CLOVER Achieves Site-Specific Integration / Expression

    Non-viral Cas-CLOVER Achieves Site-Specific Integration / Expression | POSEIDA R&D DAY 2023 Cas-CLOVER enables precise genomic integration of large transgenes in vivo Fully non-viral delivery of Cas-CLOVER mRNA, gRNAs, and donor DNA using Poseida proprietary LNP Robust luciferase signal persisted >

  71. Slide 71: Cas-CLOVER: Summary and Key Takeaways

    Slide 71: Cas-CLOVER: Summary and Key Takeaways

    Cas-CLOVER for site-specific non-viral knockouts Cas-CLOVER is delivered using Poseida’s proprietary biodegradable mRNA LNP Gene editing efficiency (>60%) and protein reduction (~85%) at PCSK9 locus is approaching the theoretical maximum following single injection Cas-CLOVER enables gene editing in

  72. Slide 72: Non-viral Delivery Platform

    Slide 72: Non-viral Delivery Platform

    Non-viral Delivery Platform Alex Schudel Research Scientist II – GTx

  73. Slide 73: Delivering DNA is Necessary for High Impact Gene Therapy

    Slide 73: Delivering DNA is Necessary for High Impact Gene Therapy

    Delivering DNA is Necessary for High Impact Gene Therapy DNA Gene Therapy Need to deliver DNA to nucleus for: Function (transcription) Genome integration (for stability) AAV and other viral-enabled systems have performed well, but are limited Non-viral delivery has benefits: Repeat dosing feasibilit

  74. Slide 74: LNPs Use Several Lipid Types to Efficiently Encapsulate Nucleic Acid

    Slide 74: LNPs Use Several Lipid Types to Efficiently Encapsulate Nucleic Acid

    LNPs Use Several Lipid Types to Efficiently Encapsulate Nucleic Acid | POSEIDA R&D DAY 2023 Lipid nanoparticle (LNP) encapsulating nucleic acid LNP Structure Formulation Composition Structural Lipid PEG Lipid Cholesterol Helper Lipids Cationic Lipid Ionizable lipid + Nucleic acid Cargo

  75. Slide 75: LNPs Are a Mature Nucleic Acid Delivery Platform

    Slide 75: LNPs Are a Mature Nucleic Acid Delivery Platform

    Lipid nanoparticle (LNP) encapsulating nucleic acid LNP Structure Nucleic acid Cargo LNPs Are a Mature Nucleic Acid Delivery Platform (mRNA, siRNA) | POSEIDA R&D DAY 2023 mRNA siRNA 1. Publication data from pubmed.gov, clinical trial data from clinicaltrials.gov; keywords "siRNA" or "mRNA"

  76. Slide 76: DNA is a Formulation Challenge for LNPs Due to Large Size

    Slide 76: DNA is a Formulation Challenge for LNPs Due to Large Size

    Nucleic acid Cargo LNP Structure DNA is a Formulation Challenge for LNPs Due to Large Size | POSEIDA R&D DAY 2023 LNP (~80-120 nm) Size Scale of Nucleic Acid: siRNA → mRNA → DNA siRNA (21 bp, ~2 nm) mRNA (1000 nt, ~10 nm) Supercoiled DNA (4000 bp, ~100 nm) Formulation Difficulty → Size →

  77. Slide 77: LNP-Mediated DNA Delivery using Design of Experiments

    Slide 77: LNP-Mediated DNA Delivery using Design of Experiments

    LNP-Mediated DNA Delivery using Design of Experiments This mathematical approach is the same for making LNPs for siRNA and mRNA and doesn’t require new technology LNP Formulations Can be Optimized For DNA Delivery | POSEIDA R&D DAY 2023 Structural Lipid Cholesterol Ionizable lipid (+) PEG Lipid Comp

  78. Slide 78: We Have the Capability of Designing a Wide Array of Lipids

    Slide 78: We Have the Capability of Designing a Wide Array of Lipids

    We Have the Capability of Designing a Wide Array of Lipids | POSEIDA R&D DAY 2023 General Lipid Structure Classical-Type Lipidioid-Type Combinatorial Synthesis Library Ionizable Cores Hydrophobe Tails Linker Hydrophobe Tail Linker Ionizable Core Inventing New Lipids for DNA Delivery Our approach has

  79. Slide 79: Inventing New Lipids for DNA Delivery

    Slide 79: Inventing New Lipids for DNA Delivery

    Inventing New Lipids for DNA Delivery We improved our lipid potency by over 1000x for in vivo delivery of luciferase DNA Built proprietary lipids which have extra-hepatic tissue tropism Next Generation Potent DNA and Extra-hepatic Lipids | POSEIDA R&D DAY 2023 1000x Improvement Lung Spleen Liver Lip

  80. Slide 80: Key Advantages of Non-viral Approach: Repeat Dosing

    Slide 80: Key Advantages of Non-viral Approach: Repeat Dosing

    Key advantages of non-viral approach: Repeat Dosing: Non-viral DNA delivery allows for precise tailoring of gene expression Repeat Dosing Capabilities of SPB Non-viral System | POSEIDA R&D DAY 2023 Dose Titration DNA + SPB Dose Durability

  81. Slide 81: SPB Enhances Expression of Gene Through Integration

    Slide 81: SPB Enhances Expression of Gene Through Integration

    SPB Enhances Expression of Gene Through Integration | POSEIDA R&D DAY 2023 Key advantages of Non-viral approach: Versatility of dosing paradigm: co-encapsulation vs dual administration with timing flexibility Co-encapsulation of mRNA SPB and DNA improves integration and transgene expression SPB-enab

  82. Slide 82: Growing Liver Platform/LNPs While Expanding to Other Tissues

    Slide 82: Growing Liver Platform/LNPs While Expanding to Other Tissues

    Growing Liver Platform/LNPs While Expanding to Other Tissues | POSEIDA R&D DAY 2023 Highlights Continued focus on expanding proprietary liver focused LNPs – building suite of different lipids available to tackling most liver-directed diseases Early Feasibility data showing ability to utilize SPB Non

  83. Slide 83: Non-viral Delivery Platform: Summary and Key Takeaways

    Slide 83: Non-viral Delivery Platform: Summary and Key Takeaways

    Significant advancement for DNA delivery and activity (expression) 10-fold improvement in DNA expression in the last 12 months Broad applicability of DNA delivery system to treat liver-relevant diseases Advancement of Poseida Proprietary LNP portfolio in past ~12 months Significant acceleration of p

  84. Slide 84: GTx Wrap Up

    Slide 84: GTx Wrap Up

    GTx Wrap Up Brent Warner President, Gene Therapy

  85. Slide 85: Robust Platform Technologies Supporting Our GTx Pipeline Programs

    Slide 85: Robust Platform Technologies Supporting Our GTx Pipeline Programs

    Robust Platform Technologies Supporting Our GTx Pipeline Programs Current Platforms Super piggyBac® (SPB) Non-viral transposon gene insertion technology SPB Hybrid AAV + LNP Gene insertion technology utilizing AAV as DNA donor Site-Specific Super piggyBac® (ssSPB) Next generation programmable gene t

  86. Slide 86: Initial Focus on Liver-Directed Gene Therapy

    Slide 86: Initial Focus on Liver-Directed Gene Therapy

    Initial Focus on Liver-Directed Gene Therapy Our In Vivo Gene Therapy Pipeline Indication Candidate Discovery Preclinical IND-Enabling GENE THERAPIES GENE THERAPIES GENE THERAPIES Ornithine Transcarbamylase Deficiency P-OTC-101 RARE LIVER DISEASE TBD HEMOPHILIA A P-FVIII-101 Phenylketonuria P-PAH-10

  87. Slide 87: Cell Therapy

    Slide 87: Cell Therapy

    Cell Therapy Devon J Shedlock, PhD February 22, 2023 CSO, Cell Therapy

  88. Slide 88: A New Class of Allogeneic CAR-T Therapy for Oncology

    Slide 88: A New Class of Allogeneic CAR-T Therapy for Oncology

    TCR knock-out MHC I knock-out TSCM Cell Self renewing Long lived Multipotent Stem Cell Memory A New Class of Allogeneic CAR-T Therapy for Oncology Innovation in Allogeneic CAR-T Cell Therapy Cell Type Matters TSCM is the ideal cell type for CAR-T due to greater safety and durability Super piggyBac®

  89. Slide 89: Powerful Platform Technologies Enable Our Allo CAR-T Pipeline

    Slide 89: Powerful Platform Technologies Enable Our Allo CAR-T Pipeline

    Powerful Platform Technologies Enable Our Allo CAR-T Pipeline | POSEIDA R&D DAY 2023 Our suite of technologies are the basis for highly differentiated allogeneic CAR-T products GENE INSERTION Non-viral system Highly efficient technology to integrate DNA in genome Large genetic cargo capacity Broad r

  90. Slide 90: Super piggyBac Delivery of a Highly Functional Multicistronic CAR Transgene

    Slide 90: Super piggyBac Delivery of a Highly Functional Multicistronic CAR Transgene

    Super piggyBac Delivery of a Highly Functional Multicistronic CAR Transgene TTAA ITR Insulator Poly(A) TTAA Insulator ITR INCORPORATES PROPRIETARY SAFETY SWITCH Rapid, dose-dependent elimination of engineered T- cells as needed Potential management of Cytokine Release Syndrome (CRS) or other Adverse

  91. Slide 91: Strategic Focus on Improved Allogeneic CAR-T Manufacturing

    Slide 91: Strategic Focus on Improved Allogeneic CAR-T Manufacturing

    P-BCMA-ALLO1 and P-MUC1C-ALLO1 Phase 1 Studies On-going Strategic Focus on Improved Allogeneic CAR-T Manufacturing HEALTHY DONOR LEUKAPHERESIS MANUFACTURING OF ALLOGENEIC CAR-T PRODUCT PRODUCT TESTING & RELEASE ADMINISTRATION OF ALLOGENEIC CAR-T PRODUCT Same-Day Patient Treatment T Cell Isolation El

  92. Slide 92: The Importance of Stem Cell Memory T Cells (TSCM)

    Slide 92: The Importance of Stem Cell Memory T Cells (TSCM)

    The Importance of Stem Cell Memory T Cells (TSCM) Not All T Cells Are Created Equally Stem Cell Memory TSCM Cell MORE DIFFERENTIATED LESS DIFFERENTIATED Products with High % of TSCM Cells: STEMNESS MATTERS Strong correlation with best responses in the clinic More gradual tumor killing with less toxi

  93. Slide 93: Our Allogeneic CAR-T Pipeline

    Slide 93: Our Allogeneic CAR-T Pipeline

    Focused on Off-the-Shelf Cell Therapies for Both Solid and Liquid Tumors Our Allogeneic CAR-T Pipeline Indication Candidate Discovery Preclinical IND-Enabling Phase 1 Phase 2 CAR-T FOR ONCOLOGY SOLID TUMOR P-MUC1C-ALLO1 P-PSMA-ALLO1 DUAL UNDISCLOSED MULTIPLE MYELOMA P-BCMA-ALLO1 P-BCMACD19-ALLO1 B C

  94. Slide 94: P-MUC1C-ALLO1 Clinical Update

    Slide 94: P-MUC1C-ALLO1 Clinical Update

    P-MUC1C-ALLO1 Clinical Update Rajesh Belani, MD Vice President, Clinical Development

  95. Slide 95: P-MUC1C-ALLO1-001 Phase 1 Trial in Solid Tumors

    Slide 95: P-MUC1C-ALLO1-001 Phase 1 Trial in Solid Tumors

    P-MUC1C-ALLO1-001 Phase 1 Trial in Solid Tumors MUC1C a unique binding target Different than other MUC1 programs Large potential patient population Strong preclinical data in breast cancer (TNBC) and ovarian cancer Ongoing dose escalation Outpatient administration allowable Early clinical data prese

  96. Slide 96: Phase 1 3+3 Dose Escalation Study Schematic

    Slide 96: Phase 1 3+3 Dose Escalation Study Schematic

    Phase 1 3+3 Dose Escalation P-MUC1C-ALLO1-001 Study Schematic If the Maximum Tolerated Dose (MTD) has not been reached in Arm A following completion of Cohort 4, the dose of P-MUC1C-ALLO1 may be increased by 5-10 x106 cells/kg for the subsequent dose levels as agreed upon with the safety committee a

  97. Slide 97: P-MUC1C-ALLO1 Cellular Product is Comprised Primarily of Stem Cell Memory T-cells

    Slide 97: P-MUC1C-ALLO1 Cellular Product is Comprised Primarily of Stem Cell Memory T-cells

    Reliably high frequency of CAR+ cells (>95%) across clinical lots P-MUC1C-ALLO1 is largely comprised of early memory T cells, i.e., TSCM and TCM (CD45RO-CD45RA+CD62L+ or CD45RO+CD45RA-CD62L+, respectively) Low composition of late memory T cells (<5%) Products are consistently >90% CCR7+ P-MUC1C-ALLO

  98. Slide 98: Patient Demographics and Characteristics

    Slide 98: Patient Demographics and Characteristics

    Patient Demographics and Characteristics (Data Cutoff 11-14-2022) P-MUC1C-ALLO1-001 Phase 1 Dose-escalation Clinical Results CAR-T cells administered, cells/kg Mean (min, max) x 106 Patients, n Cohort 1: 0.75 x 106 single infusion 74.15 (47.93, 96.98) 3 Cohort 2: 2.0 x 106 single infusion 164.15 (10

  99. Slide 99: P-MUC1C-ALLO1 Demonstrates Favorable Safety and Encouraging Efficacy

    Slide 99: P-MUC1C-ALLO1 Demonstrates Favorable Safety and Encouraging Efficacy

    P-MUC1C-ALLO1 Demonstrates Favorable Safety and Encouraging Efficacy Safety Response and Disposition Cohort/ cell dose Patient # Tumor type Lines of prior therapy, n Dose-limiting toxicities Related Grade ≥3 SAEs Best overall response (RECIST) Days on study** Status Cohort 1 0.75 x 106 cells/kg 1 Es

  100. Slide 100: P-MUC1C-ALLO1 Summary

    Slide 100: P-MUC1C-ALLO1 Summary

    P-MUC1C-ALLO1 is largely comprised of early memory T cells, i.e., TSCM and TCM Ph1 was initiated in May 2022 and is estimated to treat up to 100 patients across 15 sites Three patients in cohort 1 and 3 patients in cohort 2 have been treated Both cohort 1 and cohort 2 were completed without dose-lim

  101. Slide 101: P-BCMA-ALLO1 Clinical Update

    Slide 101: P-BCMA-ALLO1 Clinical Update

    P-BCMA-ALLO1 Clinical Update Rajesh Belani, MD Vice President, Clinical Development

  102. Slide 102: Background

    Slide 102: Background

    Background Multiple myeloma (MM) is an incurable plasma cell malignancy with high expression of B-cell Maturation Antigen (BCMA) Two autologous CAR-Ts targeting BCMA are approved for relapsed refractory MM (RRMM) Autologous CAR-T are limited by: The need for apheresis Long manufacturing times and hi

  103. Slide 103: P-BCMA-ALLO1 Allogeneic CAR-T Therapy for Multiple Myeloma

    Slide 103: P-BCMA-ALLO1 Allogeneic CAR-T Therapy for Multiple Myeloma

    Optimized for safety, efficacy and to overcome autologous CAR-T limitations Produced from healthy donor T cells Numerous patients can be treated with each manufacturing run Nonviral transposition High fidelity gene editing High proportion TSCM cells Available “on demand” P-BCMA-ALLO1 Partnered with

  104. Slide 104: Phase 1 P-BCMA-ALLO1-001 Clinical Trial in Multiple Myeloma

    Slide 104: Phase 1 P-BCMA-ALLO1-001 Clinical Trial in Multiple Myeloma

    Phase 1 P-BCMA-ALLO1-001 Clinical Trial in Multiple Myeloma Multiple learnings from autologous program informed allogeneic approach Even higher TSCM Better binder technology (utilizing VH binder) Booster molecule (lower cost) Ongoing dose escalation Early clinical data presented at ESMO-IO (Dec 2022

  105. Slide 105: P-BCMA-ALLO1-001 Dose Escalation Plan and Study Schematic

    Slide 105: P-BCMA-ALLO1-001 Dose Escalation Plan and Study Schematic

    Single infusion Dose Levels (cells/kg/dose) Cohort minus 2: 0.0625 x 106 Cohort minus 1: 0.25 x 106 Cohort 1:0.75 x 106 Cohort 2: 2 x 106 Cohort 3:6 x 106 Cohort 4: 10 x 106 Cohort 5: 15 x 106 If cohort 5 is completed without concluding an MTD, the safety Committee may elect to assess further escala

  106. Slide 106: P-BCMA-ALLO1-001 Patient Demographics and Characteristics

    Slide 106: P-BCMA-ALLO1-001 Patient Demographics and Characteristics

    P-BCMA-ALLO1-001 Patient Demographics and Characteristics CAR-T Cells Administered: Cells/kg Mean (Min/Max) x 106 Patients, n Cohort 1: 0.75 x 106 single infusion 48 (37/ 64) 7 Cohort 2: 2.0 x 106 single infusion 162 (126/210) 3 Age / Gender/ Time Since Diagnosis / Performance Status (n=10) Median (

  107. Slide 107: P-BCMA-ALLO1 Demonstrates Favorable Safety Profile

    Slide 107: P-BCMA-ALLO1 Demonstrates Favorable Safety Profile

    A total of 10 patients were treated with P-BCMA-ALLO1, 7 in cohort 1, and 3 in cohort 2 Three SAE occurred in cohort 1 (G3 Febrile Neutropenia, G3 Disseminated Herpes Zoster, G3 Cryptosporidiosis infection) No SAE were related to P-BCMA-ALLO1 No CRS, GVHD, neurotoxicity, DLT or Adverse Events of Spe

  108. Slide 108: P-BCMA-ALLO1 Demonstrates Encouraging Efficacy

    Slide 108: P-BCMA-ALLO1 Demonstrates Encouraging Efficacy

    All enrolled patients are heavily treated having received 6.5 median prior lines of therapy 3 out of 6 evaluable cohort 1 patients had received prior BCMA targeted therapy 4 out of 6 evaluable cohort 1 patients had high risk cytogenetics ORR for Cohort 1 is 50% ORR in patients who have received prio

  109. Slide 109: P-BCMA-ALLO1 Summary

    Slide 109: P-BCMA-ALLO1 Summary

    P-BCMA-ALLO1 is an allogeneic “off the shelf” BCMA targeting CAR-T therapy that demonstrates compelling anti-myeloma activity, in a heavily pretreated patient population, at the lowest dose tested, while demonstrating excellent tolerability It is active in patients who have failed prior BCMA targete

  110. Slide 110: P-CD19CD20-ALLO1

    Slide 110: P-CD19CD20-ALLO1

    P-CD19CD20-ALLO1 Stacey Cranert, PhD Director, Immuno-Oncology

  111. Slide 111: CD19/CD20 Dual CAR for Peripheral B Cell Malignancies

    Slide 111: CD19/CD20 Dual CAR for Peripheral B Cell Malignancies

    CD19/CD20 Dual CAR for Peripheral B Cell Malignancies Highly validated therapeutic targets for B cell malignancies Expression of both markers is highly restricted to the B cell lineage CD19 is a transmembrane glycoprotein of the Ig superfamily Expressed during all stages of B cell development CD20 i

  112. Slide 112: P-CD19CD20-ALLO1 Dual CAR-T: Licensed to Roche

    Slide 112: P-CD19CD20-ALLO1 Dual CAR-T: Licensed to Roche

    Licensed to Roche Poseida Project Stage: IND planned 2023 Early competitor data suggests excellent clinical activity for CD19/CD20 targeting Dual targets address limitations of single Ag loss and tumor heterogenicity, while dual CAR expression addresses structural limits of tandem configuration CD19

  113. Slide 113: P-CD19CD20-ALLO1 Allogeneic CAR-T Therapy for B cell Malignancies

    Slide 113: P-CD19CD20-ALLO1 Allogeneic CAR-T Therapy for B cell Malignancies

    Optimized for Safety and Efficacy Produced from healthy donor T cells Nonviral transposition High fidelity gene editing High proportion TSCM cells Targeted Indications: R/R DLBCL, CLL, MZL, MCL, FL, PMBCL No FDA Approved CAR-T therapy for CLL and MZL P-CD19CD20-ALLO1 Allogeneic CAR-T Therapy for B c

  114. Slide 114: P-CD19CD20-ALLO1 Demonstrates Anti-Tumor Activity In Vivo

    Slide 114: P-CD19CD20-ALLO1 Demonstrates Anti-Tumor Activity In Vivo

    P-CD19CD20-ALLO1 demonstrates Ag-specific anti-tumor activity in a dose response against multiple tumor models in vivo In Vivo Activity Against Leukemia and Lymphoma Xenografts Mec1 (B-CLL) Raji (Burkitt’s lymphoma) *Program on track for 2023 IND filing* PBS Control CAR-T Treated | POSEIDA R&D DAY 2

  115. Slide 115: P-CD19CD20-ALLO1: Summary and Key Takeaways

    Slide 115: P-CD19CD20-ALLO1: Summary and Key Takeaways

    P-CD19CD20-ALLO1 is a DUAL targeting CAR-T aiming to prevent relapse in B cell malignancies This Allogeneic CAR-T product demonstrates: Strong in vivo cytotoxicity against xenograft models of CLL and lymphoma High TSCM IND filing planned 2023 P-CD19CD20-ALLO1: Summary and Key Takeaways | POSEIDA R&D

  116. Slide 116: P-CD70-ALLO1

    Slide 116: P-CD70-ALLO1

    P-CD70-ALLO1 Julia Coronella, PhD Vice President, Immuno-Oncology

  117. Slide 117: P-CD70-ALLO1 Project Stage: Preclinical

    Slide 117: P-CD70-ALLO1 Project Stage: Preclinical

    Project stage: preclinical CD70 is highly expressed in AML (85%), NHL (90%), and RCC (80%) Highly expressed in Cutaneous T-cell lymphoma (CTCL); MF (95%), pcALCL (100%), PTCL (64%) Limited healthy tissue expression (APCs, activated T/B cells) and favorable safety record for other programs in develop

  118. Slide 118: Anti-CD70 CAR-T Cells Effectively Control Tumors in AML Xenograft

    Slide 118: Anti-CD70 CAR-T Cells Effectively Control Tumors in AML Xenograft

    Anti-CD70 CAR-T Cells Effectively Control Tumors in a Xenograft Model of AML CAR-T Treatment Tool CAR-T cells expressing binders generated from published scFv sequences were used for target proof of concept in the Nomo-1 model of AML 6/12 tool CAR-T assessed effectively slowed or controlled tumor gr

  119. Slide 119: Cas-CLOVER Editing of CD70 Locus Yields 95% KO Efficiency

    Slide 119: Cas-CLOVER Editing of CD70 Locus Yields 95% KO Efficiency

    Cas-CLOVER Editing of CD70 Locus Yields 95% KO Efficiency and Increases % TSCM in Anti-CD70 CAR-T Cells CD70 FMO No gRNA Pair 1 Pair 5 CD4+ T cells CD8+ T cells CD70 Editing Efficiency Final Product Phenotype Anti-CD70 CAR-T cells express CD70, which can lead to fratricide, activation, and/or impair

  120. Slide 120: Anti-CD70 CAR-T With CD70 KO Exhibit Improved Durability

    Slide 120: Anti-CD70 CAR-T With CD70 KO Exhibit Improved Durability

    Tool CAR-T cells with or without CD70 KO were rechallenged with a high dose of tumor after initial period of tumor control Only CD70 KO cells were able to control tumor rechallenge Anti-CD70 CAR-T With CD70 KO Exhibit Improved Durability of Response Against AML Xenografts In Vivo CAR-T Treatment | P

  121. Slide 121: P-CD70-ALLO1: Summary and Key Takeaways

    Slide 121: P-CD70-ALLO1: Summary and Key Takeaways

    Super piggyBac is used to generate anti-CD70 CAR-T cells with high TSCM and strong in vivo cytotoxicity against a xenograft model of AML Cas-CLOVER efficiently disrupts CD70 expression during CAR-T production, yielding a product with increased TSCM cell content and improved in vivo durability Anti-C

  122. Slide 122: P-ckit-ALLO1

    Slide 122: P-ckit-ALLO1

    P-ckit-ALLO1 Nina Timberlake, PhD Director, Immuno-Oncology

  123. Slide 123: P-ckit-ALLO1 Project Stage: Preclinical

    Slide 123: P-ckit-ALLO1 Project Stage: Preclinical

    Project stage: preclinical c-kit is expressed on >95% of HSCs and overexpressed in >80% of AML including on leukemic stem cells P-ckit-ALLO1 aims to increase transplant eligibility in relapsed/refractory AML patients and improve treatment efficacy and durability by specifically targeting AML stem ce

  124. Slide 124: P-ckit-ALLO1 as a Bridge to Transplant in R/R AML

    Slide 124: P-ckit-ALLO1 as a Bridge to Transplant in R/R AML

    P-ckit-ALLO1 as a Bridge to Transplant in R/R AML Engraftment with minimal immune suppression Healthy and malignant bone marrow AML stem cells Healthy stem cells CAR-T cells targeting c-kit Ablation of residual disease and stem cells Clearance of CAR-T + reduced intensity conditioning Donor HSC tran

  125. Slide 125: Potential Advantages of P-ckit-ALLO1

    Slide 125: Potential Advantages of P-ckit-ALLO1

    Potential Advantages of P-ckit-ALLO1 Bone marrow homing and preferential expansion at the site of target cells Rapid and controllable clearance of CAR-T cells using embedded safety switch Direct target cell killing with potent cytotoxic activity P-ckit-ALLO1 High systemic drug concentration may incr

  126. Slide 126: Dual Anti-c-kit CAR-T Cells Significantly Outperform Single CARs

    Slide 126: Dual Anti-c-kit CAR-T Cells Significantly Outperform Single CARs

    Dual Anti-c-kit CAR-T Cells Significantly Outperform Single CARs Dual anti-c-kit CAR-T cells exhibit increased potency compared to matched single CAR-T cells, resulting in complete tumor elimination, achieving 100% survival for more than 100 days in a xenograft model of AML CAR-T Treatment Tumor Gro

  127. Slide 127: P-cKit-ALLO1: Summary and Key Takeaways

    Slide 127: P-cKit-ALLO1: Summary and Key Takeaways

    Targeting c-kit+ cancer stem cells may improve the durability of responses in AML, which is known to originate from early bone marrow progenitors Super piggyBac enables delivery and expression of two full length c-kit targeting CARs from a single transgene Dual c-kit CAR-T cells have potent in vivo

  128. Slide 128: CAR-TCR-T for Solid Tumors

    Slide 128: CAR-TCR-T for Solid Tumors

    CAR-TCR-T for Solid Tumors Devon J Shedlock, PhD Chief Scientific Officer, Cell Therapy

  129. Slide 129: Engineered TCRs for Targeting Intracellular and Lipid Ags, and HSPs

    Slide 129: Engineered TCRs for Targeting Intracellular and Lipid Ags, and HSPs

    Engineered TCRs for Targeting Intracellular and Lipid Ags, and HSPs TCR-engineered cells express tumor-Ag-specific TCRs comprised of α- and β-, or γ- and δ-chains, which recognize Ag + MHC or lipid Ags​ and heat shock proteins TCRs access intracellular tumor antigens​ TCRs may require lower antigen

  130. Slide 130: Versatile Allogeneic CAR-TCR-T Cell Products

    Slide 130: Versatile Allogeneic CAR-TCR-T Cell Products

    Large cargo enables delivery of multiple genes for multi-targeting via CAR, abTCR, gδTCR, and/or activation-gated expression Multi-targeting 3 Combination of piggyBac®, Cas-CLOVER™ Booster molecule, and our proprietary Allo process Allogenic 2 Enabled by Our Platform Technologies and Addresses Key L

  131. Slide 131: Multiple Antigen Targeting by Combining CAR and TCR Platforms

    Slide 131: Multiple Antigen Targeting by Combining CAR and TCR Platforms

    Multiple Antigen Targeting by Combining CAR and TCR Platforms A majority of engineered T cells express both CAR and TCR POTENTIAL BENEFIT Enable engineered T cell to recognize both cell surface and intracellular antigen presented by MHC TCR CAR Simultaneous Expression of CAR and TCR Allogeneic CAR-T

  132. Slide 132: Super piggyBac-produced CAR-TCR-T Characterized by High %TSCM

    Slide 132: Super piggyBac-produced CAR-TCR-T Characterized by High %TSCM

    Super piggyBac®-produced CAR-TCR-T characterized by High %TSCM TSCM Cell TCM Cell TEM Cell TEFF Cell TN Cell Adapted from Gattinoni et al. (2017) Nat. Med. Stemness Proliferative potential Lymphoid homing Antigen independence Lipid metabolism Low Dym Senescence Cytotoxicity Tissue tropism Antigen ad

  133. Slide 133: Multiplex Gene-editing Generates Off-the-shelf Allogeneic TCR-T

    Slide 133: Multiplex Gene-editing Generates Off-the-shelf Allogeneic TCR-T

    Multiplex Gene-editing Generates “Off-the-shelf” Allogeneic TCR-T TRAC/TRBC DKO eliminates endogenous (Endo)-TCR and prevents TCR mismatching b2M KO disrupts MHC-I expression Cas-CLOVER™ mediated multiplex TCR & MHC-I KO with robust efficacy TRBC-KO TRAC-KO DKO 86 25 84 CD8a A2-NY-ESO-1-Dextramer TC

  134. Slide 134: Poseida's CD8 Co-receptor Enhances TCR Activity

    Slide 134: Poseida's CD8 Co-receptor Enhances TCR Activity

    Poseida’s CD8 Co-receptor Enhances TCR Activity in Both CD4+ and CD8 + T cells De novo chimeric homodimer CD8 co-receptor incorporates both palmitoylation domain, a lipid anchor facilitating coreceptor localization, and high-affinity Lck binding domain which recruits tyrosine Kinase to phosphorate T

  135. Slide 135: TCR-AIGES-CAR: TCR-Mediated CAR Expression for Improved Safety

    Slide 135: TCR-AIGES-CAR: TCR-Mediated CAR Expression for Improved Safety

    TCR-AIGES-CAR: TCR-Mediated CAR Expression for Improved Safety TCR CAR CAR Activation VL VH ON Potential of TCR-AIGES-CAR Limit off-tumor activity of the CAR Decrease T cell expression burden D0 (Resting) D2 Post- TCR stimulation BCMA_CAR NYESO_TCR 2.06 68 29 31 30 38 Heterogenous Tumor Car-target O

  136. Slide 136: Versatile Platform Adapted for Oncology, Infectious Disease, Autoimmune

    Slide 136: Versatile Platform Adapted for Oncology, Infectious Disease, Autoimmune

    Versatile Platform Can be Adapted for Oncology, Infectious Disease, Autoimmune, and Other Indications NY-ESO-1+ A375-melanoma Tumor Oncology: allogeneic TCR-T (no armors) exhibit remarkable in vivo efficacy in xenografted melanoma tumor model Infectious Disease: in vivo efficacy in COVID-19 infectio

  137. Slide 137: CAR-TCR-T: Summary and Key Takeaways

    Slide 137: CAR-TCR-T: Summary and Key Takeaways

    Poseida’s non-viral technologies enabled development of our Allogeneic CAR-TCR-T Platform Many advantages including multi-targeting and a high % of TSCM αβ and γδ TCRs recognize intracellular Ag-MHC and lipid Ags, respectively, providing key advantages over CAR alone CAR and TCR co-expression may be

  138. Slide 138: Conclusion and Summary

    Slide 138: Conclusion and Summary

    Conclusion and Summary Mark J. Gergen CEO

  139. Slide 139: Acknowledgements & Thank You

    Slide 139: Acknowledgements & Thank You

    Acknowledgements & Thank You Introduction Eric M. Ostertag, MD, PhD, Founder Fireside Chat George Church, PhD, Gene Editing Pioneer & Chair, Poseida Gene Therapy SAB Gene Therapy Brent Warner, President, Gene Therapy Fireside Chat Madhu Natarajan, PhD, Head, Rare Diseases Drug Discovery Unit, Takeda

  140. Slide 140: On a Mission to Redefine Cell & Gene Therapy

    Slide 140: On a Mission to Redefine Cell & Gene Therapy

    On a Mission to Redefine Cell & Gene Therapy PEOPLE Passionate and dedicated team working on treatments for patients with cancer and rare diseases PLATFORMS Innovating with powerful and differentiated genetic engineering technologies Moving Beyond Viral Vectors for Gene Therapy IN VIVO GENE THERAPY

  141. Slide 141: Novel Technologies that Deliver Differentiated Products

    Slide 141: Novel Technologies that Deliver Differentiated Products

    Novel Technologies that Deliver Differentiated Products Genetic Engineering Platforms Designed to Perform Our focus on innovation continues with ongoing improvements to all our platforms including progress on site-specific Super piggyBac for precise gene editing and insertion GENE INSERTION Non-vira

  142. Slide 142: A New Class of Allogeneic CAR-T for Oncology

    Slide 142: A New Class of Allogeneic CAR-T for Oncology

    TSCM Cell Self-renewing Long lived Multipotent Stem Cell Memory A New Class of Allogeneic CAR-T for Oncology Highly Differentiated Innovation in CAR-T Cell Type Matters TSCM is the ideal cell type for CAR-T due to greater safety and durability Super piggyBac® is the ideal non-viral gene insertion te

  143. Slide 143: A New Class of Products for Rare Diseases and Hard-to-Treat Populations

    Slide 143: A New Class of Products for Rare Diseases and Hard-to-Treat Populations

    A New Class of Products for Rare Diseases and Hard-to-Treat Populations Disruption in Gene Therapy Fully Integrating piggyBac integrates into DNA enabling the potential for single treatment cures Addressing Challenges of Viral Delivery piggyBac and Nanoparticle technology can address limitations of

  144. Slide 144: Leveraging the Power of Products, Partnerships, People and Platforms

    Slide 144: Leveraging the Power of Products, Partnerships, People and Platforms

    Leveraging the Power of Products, Partnerships, People and Platforms Advancing a New Class of Cell Therapy and Gene Therapy Products CELL THERAPY FOR ONCOLOGY GENE THERAPY / GENE EDITING Strong innovation engine, dedicated people and powerful differentiated platform technologies drive our opportunit

  145. Slide 145: Q&A

    Slide 145: Q&A

    Q&A

Source: SEC EDGAR · 8-K filed Feb 22, 2023

More decks from Poseida Therapeutics Inc